News

The great medicines migration: how China controls key drug supplies

In the spring of 2020, as the Covid-19 pandemic took hold, many pharmaceutical companies faced disruptions to their supply chains. Chemicals used to produce the key ingredients in drugs were often sourced from only a few suppliers in China — sometimes from just one.

The pandemic has brought to light just how much the global pharmaceutical supply chain depends on China, even for the most basic ingredients.

This is the final instalment of a Nikkei Asia series on Beijing’s aim to become the centre of the global drug industry. This instalment focuses on China’s market command for active pharmaceutical ingredients — a dominance some western countries are challenging as Covid-19 and geopolitical tensions expose supply-chain vulnerabilities.

Read more here.

A version of this article was first published by Nikkei Asia on April 5 2022. ©2022 Nikkei Inc. All rights reserved

Articles You May Like

Public services will wither unless the UK makes hard tax choices
3 strategies investors might use to trade the upcoming Ethereum Merge
Electric power, healthcare showed greatest growth in first half
Ethereum ICO-era whale address transfer 145,000 ETH weeks before the Merge
Lisa Gorab, a New Jersey bond counsel ‘trailblazer,’ is remembered